focus -WSS

focus

author：knowledge 2025-09-28 04:13:02 - browse：1164

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Senators: Long

knowledge

WSS

What to know about Saharan dust affecting the US and how it can affect health

As Taiwan prepares for anti

Hearing on Medicare drug price negotiation gets unusually heated

STAT Virtual Event: Putting AI to the Test

Experts study whether long Covid risk adds up with each reinfection

Vatican is moving ahead with plan to reunite Ukrainian children taken to Russia with their families

explore

focus

focus

Supreme Court strikes down use of affirmative action

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

Continuity nursing helped my family in our darkest PICU moments

STAT Virtual Event: Putting AI to the Test

Heart attack and stroke risk calculators need revising

Biotech lab space demand falls sharply

Trump demands the U.S. pay no more for drugs than other countries … again

What to know about Saharan dust affecting the US and how it can affect health

United colonoscopy coverage change 'may cost lives,' doctors say

Will.i.am, Britney Spears release new single, 'Mind Your Business'

focus

How artificial intelligence is being used to detect, treat cancer

Readout LOUD podcast: possible new ALS drug, artificial wombs

Experts study whether long Covid risk adds up with each reinfection

In new study, freeze

Hearing on Medicare drug price negotiation gets unusually heated

A double vaccine crisis is endangering millions of children

hotspot

leisure time

knowledge

Wikipedia